Literature DB >> 21756451

[Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec].

Emmanuel Stip1, Amal Abdel-Baki, David Bloom, Sylvain Grignon, Marc-André Roy.   

Abstract

OBJECTIVE: To present points of agreement and disagreement about antipsychotics. Since the appearance of 2nd generation long-acting antipsychotics (LAA), and given the high frequency of noncompliance with antipsychotics in psychotic disorders, LAAs have attracted more interest in psychiatric literature. However,their use is suboptimal, globally, and is also subject to significant national disparities. ln this context,the Association des médecins psychiatres du Québec (AMPQ) has asked for a review of the evidence concerning LAA efficiency and tolerance, and has called for consensual c1inical reflection on the benefits and obstacles of prescribing them, as weil as potential solutions, including administrative and judiciary dimensions.
METHODS: The AMPQ established an expert committee, from 4 Quebec universities, which was responsible for preparing the review paper. The committee intended to appropriately provide c1inicians with the different aspects of LAA use. The committee produced a qualitative and selective review.
RESULTS: Mean LAA prescription rates observed in Canada are around 6% and data to confirm this are scarce. A 15% to 25% rate could be suggested.
CONCLUSION: The committee has submitted the Quebec long-acting antipsychotic algorithm (QAAPAPLE, derived from the French acronym) as a result of the consensus reached by the 4 university psychiatry departments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756451     DOI: 10.1177/070674371105600608

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  14 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal.

Authors:  Emmanuel Stip; Stéphane Potvin
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

3.  The Evolution of Long-Acting Antipsychotics Use in Québec between 2003 and 2017.

Authors:  Marc-André Roy
Journal:  Can J Psychiatry       Date:  2020-02-07       Impact factor: 4.356

4.  Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis.

Authors:  Sofia Medrano; Amal Abdel-Baki; Emmanuel Stip; Stéphane Potvin
Journal:  Psychopharmacol Bull       Date:  2018-06-20

5.  Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia.

Authors:  Jean Lachaine; Marie-Eve Lapierre; Nadine Abdalla; Alice Rouleau; Emmanuel Stip
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

6.  Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Authors:  Pierre Michel Llorca; Mocrane Abbar; Philippe Courtet; Sebastien Guillaume; Sylvie Lancrenon; Ludovic Samalin
Journal:  BMC Psychiatry       Date:  2013-12-20       Impact factor: 3.630

Review 7.  Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review.

Authors:  Saínza García; Mónica Martínez-Cengotitabengoa; Saioa López-Zurbano; Iñaki Zorrilla; Purificación López; Eduard Vieta; Ana González-Pinto
Journal:  J Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.153

8.  Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec.

Authors:  Emmanuel Stip; Jean Lachaine
Journal:  Ther Adv Psychopharmacol       Date:  2018-06-22

9.  Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia.

Authors:  Annie Viala; Françoise Cornic; Marie-Noëlle Vacheron
Journal:  Schizophr Res Treatment       Date:  2012-04-03

10.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.